July 31, 2014 | The regenerative medicine developer Macrocure raised $54 million in its NASDAQ IPO, offering up 5.35 million shares at $10 a pop. The share price was below the average of between $13-15 that company had originally planned. The Macrocure shares will trade under the ticker “MCUR” with the company granting underwriters 30 days to purchase up to 802, 500 additional sales before the offering closes out on August 5th. Credit Suisse Securities (USA) and Jefferies LLC are the joint book-running managers for the offering, with Nomura Securities International and Oppenheimer & Co. acting as co-managers. Macrocure has developed a system for treating hard-to-heal wounds using white blood cells taken from donor blood, a product called CureXcell.